美国大麻素作为治疗剂的发展
Conor H Murray1, Brenda M Gannon2, Peter J Winsauer2
1UCLA Center for Cannabis and Cannabinoids, Jane and Terry Semel Institute for Neuroscience and Human Behavior, Departments of Psychiatry and Biobehavioral Sciences (C.H.M.) and Departments of Anesthesiology and Perioperative Medicine (Z.D.C.), David Geffen School of Medicine, University of California, Los Angeles, California; Department of Pharmacology and Toxicology, College of Medicine (B.M.G.) and Office of Research Regulatory Affairs, Division of Research and Innovation (B.M.G.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; Departments of Pharmacology and Experimental Therapeutics and Biochemistry and Molecular Biology, School of Medicine (P.J.W.), and Alcohol and Drug Abuse Center of Excellence (P.J.W.) Louisiana State University Health Sciences Center, New Orleans, Louisiana; and Regulatory and Drug Development Consulting, Allucent, Carey, North Carolina (M.S.D.) conormurray@mednet.ucla.edu.
本综述探讨了THC和CBD等植物性大麻素的治疗潜力和风险,强调它们与内分泌系统的相互作用. 它强调了在大麻素药物开发中需要严格的研究设计,以获得更安全的患者结果.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 药物开发 药物开发
背景情况:
- 大麻衍生的植物性cannabinoids与人类内分泌系统相互作用,影响身体和心理健康.
- 这种相互作用提供了治疗机会,但也存在与非医疗用途相关的风险.
- 了解这些影响对于医疗应用和公共卫生都至关重要.
研究的目的:
- 综合目前关于主要和次要植物性大麻素治疗和不良影响的证据.
- 审查美国对大麻素的药物开发考虑.
- 提出临床研究设计标准,以提高科学严谨性.
主要方法:
- 对非临床和临床研究进行广泛的叙述性综述.
- 对止痛效应和神经认知风险进行了集中分析.
- 检查现有的药物开发框架.
主要成果:
- 已有证据表明,大麻素在急性暴露后具有镇痛作用.
- 确定了与急性和慢性大麻素使用相关的神经认知风险.
- 强调了治疗效益和不良影响的双重潜力.
结论:
- 植物大麻素具有治疗潜力,但需要仔细考虑风险.
- 标准化的临床研究设计对于可复制的大麻素研究至关重要.
- 需要进一步的研究,以充分阐明患者护理的风险益处概况.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Preclinical Development: Overview
Clinical Trials: Overview
Analgesia and Pain Management
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...


